Compugen Ltd. (CGEN)

1,9000 +0,0200 (+1,06%) Alla chiusura: 04:00PM EDT

Compugen Ltd.

Azrieli Center
Building D 26 Harokmim Street
Holon 5885849
Israel
972 3 765 8585
https://cgen.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 68

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Anat Cohen-Dayag Ph.D.	CEO, President & Director	796,52k	N/D	1967
Dr. Zurit Levine Ph.D.	Senior Vice President of Technology Innovation	345,7k	N/D	1968
Dr. Pierre Ferre Ph.D.	Vice President of Preclinical Development	415,1k	N/D	1977
Mr. Alberto Sessa	Chief Financial Officer	N/D	N/D	1962
Dr. Eran Ophir Ph.D.	Chief Scientific Officer	N/D	N/D	1978
Ms. Yvonne Naughton	Head of Investor Relations & Corporate Communications	N/D	N/D	N/D
Mr. Eran Ben Dor	General Counsel & Corporate Secretary	N/D	N/D	N/D
Ms. Dorit Amitay	Vice President of Human Resources	N/D	N/D	1968
Dr. Yaron Turpaz M.B.A., Ph.D.	Senior VP & Senior Advisor of Data and Informatics Solutions	N/D	N/D	1971
Rivka Schwartz	Vice President Research and Discovery	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Governance aziendale

L'ISS Governance QualityScore di Compugen Ltd. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.